Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03517176
Recruitment Status : Completed
First Posted : May 7, 2018
Last Update Posted : October 27, 2020
Information provided by (Responsible Party):
DrugCendR Inc.